Saskia du Pre

Dr. Saskia du Pre

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JOJason Oliver
Jason Oliver
GSGraham E. M. Sibley
Graham E. M. Sibley
NBNicola Beckmann
Nicola Beckmann
KDKatharine S. Dobb
Katharine S. Dobb
MSMartin J. Slater
Martin J. Slater
MBMike Birch
Mike Birch
There is an important medical need for new antifungal agents with novel mechanisms of action to treat the increasing number of patients with life-threatening systemic fungal disease and to overcome the growing problem of resistance to current therapies. F901318, the leading representative of a novel class of drug, the orotomides, is an antifungal drug in clinical development that demonstrates excellent potency against a broad range of dimorphic and filamentous fungi. In vitro susceptibility testing of F901318 against more than 100 strains from the four main pathogenic Aspergillus spp. revealed minimal inhibitory concentrations of ≤0.06 µg/mL—greater potency than the leading antifungal classes. An investigation into the mechanism of action of F901318 found that it acts via inhibition of the pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase (DHODH) in a fungal-specific manner. Homology modeling of Aspergillus fumigatus DHODH has identified a predicted binding mode of the inhibitor and important interacting amino acid residues. In a murine pulmonary model of aspergillosis, F901318 displays in vivo efficacy against a strain of A. fumigatus sensitive to the azole class of antifungals and a strain displaying an azole-resistant phenotype. F901318 is currently in late Phase 1 clinical trials, offering hope that the antifungal armamentarium can be expanded to include a class of agent with a mechanism of action distinct from currently marketed antifungals.

1 August 2018 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
SPSaskia du Pre
Saskia du Pre
NBNicola Beckmann
Nicola Beckmann
MAMariana Cruz Almeida
Mariana Cruz Almeida
GSGraham E. M. Sibley
Graham E. M. Sibley
DLDerek Law
Derek Law
JOJason D. Oliver
Jason D. Oliver
F901318 (olorofim) is a novel antifungal drug that is highly active against Aspergillus species. Belonging to a new class of antifungals called the orotomides, F901318 targets dihydroorotate dehydrogenase (DHODH) in the de novo pyrimidine biosynthesis pathway.

10 April 2020 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
SPSaskia du Pre
Saskia du Pre
MBMike Birch
Mike Birch
DLDerek Law
Derek Law
NBNicola Beckmann
Nicola Beckmann
GSGraham Sibley
Graham Sibley
JOJason Oliver
Jason Oliver
The first characterized antifungal in the orotomide class is olorofim. It targets the de novo pyrimidine biosynthesis pathway by inhibiting dihydroorotate dehydrogenase (DHODH). The pyrimidines uracil, thymine and cytosine are the building blocks of DNA and RNA; thus, inhibition of their synthesis is likely to have multiple effects, including affecting cell cycle regulation and protein synthesis. Additionally, uridine-5′-triphosphate (UTP) is required for the formation of uridine-diphosphate glucose (UDP-glucose), which is an important precursor for several cell wall components. In this study, the dynamic effects of olorofim treatment on the morphology and organization of Aspergillus fumigatus hyphae were analyzed microscopically using confocal live-cell imaging. Treatment with olorofim led to increased chitin content in the cell wall, increased septation, enlargement of vacuoles and inhibition of mitosis. Furthermore, vesicle-like structures, which could not be stained or visualized with a range of membrane- or vacuole-selective dyes, were found in treated hyphae. A colocalization study of DHODH and MitoTracker Red FM confirmed for the first time that A. fumigatus DHODH is localized in the mitochondria. Overall, olorofim treatment was found to significantly influence the dynamic structure and organization of A. fumigatus hyphae.

18 April 2017 in FEBS Letters
Verified
Journal Article
Open access
PDF file
EAEbru Alazi
Ebru Alazi
CKClaire Khosravi
Claire Khosravi
THTim G. Homan
Tim G. Homan
SPSaskia du Pre
Saskia du Pre
MAMark Arentshorst
Mark Arentshorst
Arthur RamArthur Ram
Arthur Ram
In Aspergillus niger, the enzymes encoded by gaaA, gaaB, and gaaC catabolize d‐galacturonic acid (GA) consecutively into l‐galactonate, 2‐keto‐3‐deoxy‐l‐galactonate, pyruvate, and l‐glyceraldehyde, while GaaD converts l‐glyceraldehyde to glycerol. Deletion of gaaB or gaaC results in severely impaired growth on GA and accumulation of l‐galactonate and 2‐keto‐3‐deoxy‐l‐galactonate, respectively. Expression levels of GA‐responsive genes are specifically elevated in the ∆gaaC mutant on GA as compared to the reference strain and other GA catabolic pathway deletion mutants. This indicates that 2‐keto‐3‐deoxy‐l‐galactonate is the inducer of genes required for GA utilization.

7 January 2022 in Fungal Biology Reviews
Verified
Journal Article
Open access
SPSaskia du Pre
Saskia du Pre
TDTanya Dogra
Tanya Dogra
WSWendy Laureijssen-van de Sande
Wendy Laureijssen-van de Sande